ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast CancerGlobeNewsWire • 08/15/22
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal CancerGlobeNewsWire • 08/11/22
ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational HighlightsGlobeNewsWire • 08/08/22
ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell CarcinomaGlobeNewsWire • 08/01/22
Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid TumorsBusiness Wire • 07/28/22
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid LeukemiaGlobeNewsWire • 06/29/22
ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational HighlightsGlobeNewsWire • 05/09/22
ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming MilestonesGlobeNewsWire • 02/28/22
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction CancerGlobeNewsWire • 01/27/22
ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic SyndromeGlobeNewsWire • 12/12/21
ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational HighlightsGlobeNewsWire • 11/11/21
ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual MeetingGlobeNewsWire • 11/04/21
ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBioGlobeNewsWire • 10/07/21
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid TumorsBusiness Wire • 10/05/21
ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin LymphomaGlobeNewsWire • 09/16/21